Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Valganciclovir
Drug ID BADD_D02326
Description Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Indications and Usage Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
Marketing Status approved; investigational
ATC Code J05AB14
DrugBank ID DB01610
KEGG ID D02495
MeSH ID D000077562
PubChem ID 135413535
TTD Drug ID D06GWF
NDC Product Code 69097-277; 31722-832; 50268-787; 60429-846; 70069-810; 71921-210; 27241-158; 55111-762; 61269-480; 0004-0038; 70010-051; 0904-6796; 63739-076; 68084-965; 71151-003
UNII GCU97FKN3R
Synonyms Valganciclovir | Ganciclovir L-valyl Ester | Ganciclovir L valyl Ester | Valcyt | Valganciclovir Hydrochloride | Valcyte
Chemical Information
Molecular Formula C14H22N6O5
CAS Registry Number 175865-60-8
SMILES CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Night sweats08.01.03.031; 23.02.03.006---
Oedema08.01.07.006; 14.05.06.010---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oesophageal candidiasis07.19.06.001; 11.03.03.008---
Oesophagitis07.08.05.001--
Oral candidiasis07.05.07.001; 11.03.03.004---
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003---
Paraesthesia17.02.06.005; 23.03.03.094--
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Phlebitis12.02.01.002; 24.12.03.004--
Photosensitivity reaction23.03.09.003--
Pleural effusion22.05.02.002--
Pneumonia11.01.09.003; 22.07.01.003---
Pollakiuria20.02.02.007--
Postoperative wound infection11.01.08.008; 12.02.05.011---
Productive cough22.02.03.005--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Renal failure20.01.03.005---
Retinal detachment06.09.03.003; 12.01.04.004--
Rhinorrhoea22.12.03.021--
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sinus congestion22.04.06.001---
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.003--
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages